ES2189456T3 - Composicion acuosa inyectable. - Google Patents

Composicion acuosa inyectable.

Info

Publication number
ES2189456T3
ES2189456T3 ES99936748T ES99936748T ES2189456T3 ES 2189456 T3 ES2189456 T3 ES 2189456T3 ES 99936748 T ES99936748 T ES 99936748T ES 99936748 T ES99936748 T ES 99936748T ES 2189456 T3 ES2189456 T3 ES 2189456T3
Authority
ES
Spain
Prior art keywords
injectable
waterproof composition
ticlopidin
solutol
clopidogrel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99936748T
Other languages
English (en)
Inventor
Claude Aleman
Thierry Breul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2189456T3 publication Critical patent/ES2189456T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Composición acuosa inyectable caracterizada porque contiene a título de principio activo una sal farmacéuticamente aceptable de clopidogrel o ticlopidina, poloxamer 188, copolímero de óxido de etileno y de óxido de propileno (masa molecular = 8350) comercializado bajo el nombre de Pluronic F68R, un agente básico modificador del pH compatible con la administración por inyección y polioxietilenoglico 660-12-hidroxiestearato comercializado bajo el nombre de Solutol HS 15R.
ES99936748T 1998-08-20 1999-08-18 Composicion acuosa inyectable. Expired - Lifetime ES2189456T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9810567A FR2782455B3 (fr) 1998-08-20 1998-08-20 Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine

Publications (1)

Publication Number Publication Date
ES2189456T3 true ES2189456T3 (es) 2003-07-01

Family

ID=9529788

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99936748T Expired - Lifetime ES2189456T3 (es) 1998-08-20 1999-08-18 Composicion acuosa inyectable.

Country Status (9)

Country Link
EP (1) EP1105102B8 (es)
AT (1) ATE230258T1 (es)
AU (1) AU5173699A (es)
DE (1) DE69904727T2 (es)
DK (1) DK1105102T3 (es)
ES (1) ES2189456T3 (es)
FR (1) FR2782455B3 (es)
PT (1) PT1105102E (es)
WO (1) WO2000010534A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US6413537B1 (en) * 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
AU2003238664A1 (en) 2003-03-12 2004-09-30 Cadila Healthcare Limited Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
DK1610822T4 (en) 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
EP1638595B1 (en) 2003-06-20 2013-03-20 Ares Trading S.A. Freeze-dried fsh / lh formulations
ES2337918T3 (es) * 2006-04-13 2010-04-30 Riemser Specialty Production Gmbh Poloxameros como lubricantes para composiciones farmaceuticas que contienen derivados de tieno(3,2-c)piridina.
GB0804242D0 (en) * 2008-03-07 2008-04-16 Rosemont Pharmaceuticals Ltd Clopidogrel solution
EP2107061A1 (en) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
WO2009133455A2 (en) * 2008-05-01 2009-11-05 Cadila Healthcare Limited Pharmaceutical composition of clodipogrel
FR2932387B1 (fr) * 2008-06-16 2010-09-17 Cll Pharma Composition orale contenant un agent anti-plaquettaire de la famille des thienopyridines sous forme de base.
WO2011071853A2 (en) * 2009-12-07 2011-06-16 Academic Pharmaceuticals Incorporated Parenteral formulation of clopidogrel
WO2011101865A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Stable pharmaceutical compositions of clopidogrel for parenteral delivery
US20230059869A1 (en) 2021-08-03 2023-02-23 Liqmeds Worldwide Limited Oral pharmaceutical solution of clopidogrel
TW202339745A (zh) 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE188870T1 (de) * 1994-10-04 2000-02-15 Lohmann Rudolf Lomapharm Lösungen von anthrachinonen zur parenteralen applikation
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable

Also Published As

Publication number Publication date
FR2782455B3 (fr) 2000-09-15
DE69904727D1 (de) 2003-02-06
FR2782455A1 (fr) 2000-02-25
EP1105102A1 (fr) 2001-06-13
PT1105102E (pt) 2003-04-30
EP1105102B1 (fr) 2003-01-02
EP1105102B8 (fr) 2003-08-06
AU5173699A (en) 2000-03-14
DK1105102T3 (da) 2003-04-22
DE69904727T2 (de) 2003-11-13
WO2000010534A1 (fr) 2000-03-02
ATE230258T1 (de) 2003-01-15

Similar Documents

Publication Publication Date Title
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
ES2189456T3 (es) Composicion acuosa inyectable.
HRP20060240T3 (hr) Intranazalni pripravak rotigotina
DZ2964A1 (fr) Diphénylurées substituées nouvelles, et compositions pharmaceutiques les contenant.
ATE464049T1 (de) Pharmazeutische kombinationen von hydrocodon und naltrexon
DE69942154D1 (de) Medikamenthaltige zusammensetzung in aerosolform
ATE419039T1 (de) Pharmazeutische kombinationen von oxycodon und naloxon
HUP0302997A3 (en) Phenylalanine derivatives with alpha4-integrin effect, pharmaceutical compositions containing them and their use
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
EE200200522A (et) Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina
TR200201174T2 (tr) Florokinolon antibiyotik ilacı ve iksantan zamkı içeren farmasötik bileşimler.
IL152094A0 (en) Ecteinascidin derivatives and pharmaceutical compositions containing the same
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
DE60019334D1 (de) Antivirale arznei
BR0213379A (pt) Formulação resistente a derramamento de mascaramento de gosto
ZA200208761B (en) Pharmaceutical form of administration for peptides, methods for its production and use.
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
PL346764A1 (en) New oral formulation for 5-ht4
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
ZA200309513B (en) Novel heterocyclic derivatives and medicinal use thereof.
HUP0203903A3 (en) Solubilized pharmaceutical composition for parenteral administration and its use
FR12C0064I2 (fr) Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
EP1283042A4 (en) AQUEOUS FLUID PREPARATION